Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms.

about

Pharmacogenetics in the treatment of pre-eclampsia: current findings, challenges and perspectives.Assessment of angiogenesis modulators in pregnant women with pre-eclampsia: a case–control study

P2860

Q39208841-62DA764E-9B95-479B-B124-56A1AC49F055 Q56449434-B7F99DF4-FEA0-4774-98C2-95E82C19CC39

P2860

Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms.

Item

http://www.wikidata.org/entity/Q45364397

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms.

@en

Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms.

@nl

type

Item

label

Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms.

@en

Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms.

@nl

prefLabel

Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms.

@en

Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms.

@nl

P1476

Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms.

@en

P2093

Ana C T Palei

http://www.w3.org/2001/XMLSchema#string

Jose E Tanus-Santos

http://www.w3.org/2001/XMLSchema#string

Nibia Eleuterio

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR)

Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor

The biology of VEGF and its receptors

Soluble endoglin contributes to the pathogenesis of preeclampsia

Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy

Susceptible and protective eNOS haplotypes in hypertensive black and white subjects

Endothelial nitric oxide synthase haplotypes affect the susceptibility to hypertension in patients with type 2 diabetes mellitus

Definition and clinical importance of haplotypes

Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia

Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src.

P2888

s00404-014-3475-2

P304

799-803

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00404-014-3475-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

291

http://www.w3.org/2001/XMLSchema#string

P50

Ricardo Cavalli

Valeria C Sandrim

P577

2014-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1001706727

http://www.w3.org/2001/XMLSchema#string

P698

25234518

http://www.w3.org/2001/XMLSchema#string

P921

pre-eclampsia

Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms.

about

P2860

P2860

Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921